Aligos Therapeutics, Inc.

Analysis for Ticker: ALGS

Aligos Therapeutics Inc attempts to develop drugs for chronic hepatitis B and liver diseases, but the math reveals a company designed to burn money instead of curing people. They have built a financial furnace that has incinerated 642$ million since they started, without ever selling a single product. Imagine a lemonade stand that spends 60,7$ million on fancy cups and rent in nine months but never actually sells any lemonade. This is the mathematical reality for a business with a total market value of only 54,08$ million. The money does not just disappear into science; it is funneled through complex contracts that ensure universities and insiders get paid while the bank account of the company drains toward zero.